Oncology

Pazopanib was effective and tolerated among patients with advanced renal cell carcinoma and a poor ECOG performance status, and may serve as a potential treatment option for patients who are unable to tolerate or receive immune checkpoint inhibitor drugs. Patients diagnosed with advanced renal cell carcinoma (aRCC) exhibit poor Eastern Cooperative Oncology Group (ECOG) performance...

Combined administration of metformin and intensive-exercise diet therapy is a useful approach for improving islet function and metabolism of glucose and lipids in diabetic renal cancer carcinoma patients, according to this study. Tumor progression is higher in individuals suffering from diabetes mellitus (DM) than in nondiabetic patients owing to impaired immune system functioning. Metformin is...

The combination of MEDI0680 and durvalumab was well-tolerated and safe but did not show any significant improvement in effectiveness compared to nivolumab monotherapy, in this study. Renal cell carcinoma (RCC) accounts for 2–3% of all adult malignancies. Advanced or metastatic RCC has a poor prognosis, and standard-of-care treatment options are limited. Immunotherapy has emerged as...

The combination therapy of BEMPEG plus NIVO has shown promising results in treating advanced renal cell carcinoma. Although surgery and radiation therapy are the primary treatments for renal cell carcinoma (RCC), the introduction of immunotherapy has transformed the treatment landscape for advanced RCC. BEMPEG plus NIVO is a combination therapy with promising results in treating...

Nivolumab monotherapy produced a modest response rate in patients with nccRCC, with higher response rates observed in patients with higher PD-L1 expression. In 2015, the FDA approved nivolumab monotherapy for treating clear cell renal cell carcinoma (ccRCC) patients who are resistant to vascular endothelial growth factor receptor tyrosine kinase inhibitors. A trial examined the effectiveness...

For individuals with metastatic renal cell carcinoma who have progressed on earlier regimens, such as axitinib, this study found Tivozanib to be effective. Metastatic renal cell carcinoma (mRCC) is a challenging and complex disease to manage. Recent advancements in mRCC management have led to combinations of immune checkpoint inhibitors and vascular endothelial growth factor receptor-tyrosine...

This study found that, over time, treatment with sunitinib resulted in an increasing prevalence of hypogonadism among male patients diagnosed with metastatic renal cell carcinoma. However, administering testosterone replacement therapy led to clinically significant improvements in quality of life. Metastatic renal cell carcinoma (mRCC) is a challenging disease to treat, and single-agent tyrosine kinase inhibitors...

Despite significant progress in multiple myeloma treatment, access to these cutting-edge therapies remains largely influenced by socioeconomic status. Individuals with low income living in economically deprived areas often experience worse outcomes. Novel therapies have improved the prognosis for patients with multiple myeloma (MM), but there are still socioeconomic disparities in patient outcomes in the United...

Swallowing exercises and training during radiotherapy show inconclusive results, but benefits were observed in other areas, including mouth opening and mental health. Head and neck cancer (HNC) can significantly impact a person’s ability to swallow, nutritional status, physical function, and overall quality of life. A randomized controlled trial noted a decline in chronic dysphagia prevalence...